AWM
XENE icon

Accel Wealth Management’s Xenon Pharmaceuticals XENE Stock Holding History

Accel Wealth Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,900
Closed -$60K – 942
2021
Q3 		$60K Buy
+3,900
New +$67.8K 0.04% 296
2021
Q1 		– Sell
-9,000
Closed -$138K – 902
2020
Q4 		$138K Buy
+9,000
New +$105K 0.13% 165

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Accel Wealth Management's XENE Position: Q4 2021 in Review

Accel Wealth Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2021, closing a stake of 3,900 shares — an estimated $60K sold.

Accel Wealth Management first reported a position in XENE in Q4 2020 and held it in 2 quarters. The position peaked at $138K in Q4 2020. 130 funds tracked by Wall St. Rank hold XENE as of Q4 2021.

  • Accel Wealth Management reported no remaining Xenon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Accel Wealth Management sold 3,900 Xenon Pharmaceuticals shares in Q4 2021, an estimated $60K.
  • Accel Wealth Management first reported a position in Xenon Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Accel Wealth Management's Xenon Pharmaceuticals position peaked at $138K in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2021.

Based on Accel Wealth Management's 13F filing for Q4 2021, filed 18 Jan 2022.